CoChat
Sign Up
Cited by 122Sleep and related disordersSleep and Wakefulness ResearchTreatment of Major Depression

The effects of paroxetine and nefazodone on sleep: a placebo controlled trial

Sharpley, A. L., Williamson, D. J., Attenburrow, M. E. J., Pearson, G., Sargent, P., Cowen, P. J.·1996·Psychopharmacology
DOI 10.1007/bf02246410
Open this paper in CoChat — free account

Abstract

We studied the effect of acute (1 day) and subacute (16 days) administration of the new antidepressant, nefazodone (400 mg daily), and the selective serotonin re-uptake inhibitor (SSRI), paroxetine (30 mg daily), on the sleep polysomnogram of 37 healthy volunteers using a random allocation, double-blind, placebo-controlled design. Compared to placebo, paroxetine lowered rapid eye movement (REM) sleep and increased REM latency. In addition, paroxetine increased awakenings and reduced Actual Sleep Time and Sleep Efficiency. In contrast, nefazodone did not alter REM sleep and had little effect on measures of sleep continuity. We conclude that in contrast to typical SSRIs, nefazodone administration has little effect on sleep architecture in healthy volunteers.

Integrity signals

Registry

Crossref · 10.1007/bf02246410

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Greater suppression of REM sleep was observed for paroxetine (30mg) than for nefazodone (400mg).

    “(Sharpley et al., 1996) observed greater suppression of REM sleep for paroxetine (30mg) than for nefazodone (400mg).”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Sharpley et al., 1996

  • In the same study, REM sleep minutes were significantly reduced and REM latency significantly prolonged at all time points examined (days 1, 6, and 16) for the paroxetine-treated group.

    “REM sleep minutes were significantly reduced and REM latency significantly prolonged at all time points examined (days 1, 6, and 16) for the paroxetine-treated group.”

    From Depression, sleep physiology, and antidepressant drugs (2001) · cites this paper as Sharpley et al., 1996

  • Compared to placebo, paroxetine in healthy volunteers produced a significant reduction in actual sleep time, a reduction in sleep efficiency, and an increase in WASO.

    “Compared to placebo, subjects receiving paroxetine demonstrated a significant reduction in actual sleep time, a reduction in sleep efficiency, and an increase in WASO.”

    From Depression, sleep physiology, and antidepressant drugs (2001) · cites this paper as Sharpley et al., 1996

  • Nefazodone exerts minimal effects in altering sleep continuity measures; it either decreases awake and movement time and number of awakenings, increases sleep efficiency, or has no effect on these parameters, thus preserving sleep continuity.

    “First, nefazodone exerts minimal effects in altering sleep continuity measures.In this regard, nefazodone either decreases awake and movement time and number of awakenings, increases sleep efficiency, or has no effect on these parameters, thus preserving sleep continuity [Armitage et al., 1994[Armitage et al., , 1997;;Gillin et al., 1997;Sharpley et al., 1992Sharpley et al., , 1996;;Rush et al., 1”

    From Depression, sleep physiology, and antidepressant drugs (2001) · cites this paper as Sharpley et al., 1996

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. Armitage R, Rush AJ, Trivedi M, Cain J, Roffwarg HP (1994) The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 10:123–127 · DOI · Paper page
  2. Friston KJ, Sharpley AL, Solomon RA, Cowen PJ (1989) Lithium increases slow wave sleep: possible mediation by brain 5-HT2 receptors? Psychopharmacology 98:139–140 · DOI
  3. Gillin JC, Wyatt RJ, Fram D, Snyder F (1978) The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline. Psychopharmacology 59:267–272 · DOI
  4. Kahn RS, Wetzler S (1991)m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30:1139–1166 · DOI
  5. Katsuda Y, Walsh AES, Ware CJ, Cowen PJ, Sharpley AL (1993) meta-chlorophenylpiperazine decreases slow-wave sleep in humans. Biol Psychiatry 33:49–51 · DOI
  6. Kupfer DJ, Spiker DG, Coble PA, Neil JF, Ulrich R, Shaw DH (1981) Sleep and treatment prediction in endogenous depression. Am J Psychiatry 138:429–433 · DOI
  7. Kupfer DJ, Perel JM, Pollock BG, Nathan RS, Grochocinski BJ, Wilson MJ, McEacharn AB (1991) Fluvoxamine versus desipramine comparative polysomnographic effects. Biol Psychiatry 29:23–40 · DOI · Paper page
  8. Lawlor BA, Newhouse PA, Balkin TJ, Molchan SE, Mellow AM, Murphy DL, Sunderland T (1991) A preliminary study of the effects of night-time administration of the serotonin agonist, m-CPP, on sleep architecture and behaviour in healthy volunteers. Biol Psychiatry 29:281–286 · DOI · Paper page
  9. Montgomery I, Oswald I, Morgan K, Adam K (1983) Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 16:139–144 · DOI · Paper page
  10. Monti JM (1989) Effects of a reversible monoamine oxidase-A inhibitor (moclobemide) on sleep of depressed patients. Br J Psychiatry 155:61–65 · DOI · Paper page
  11. Nicholson AN, Pascoe PA (1986) 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. Neuropharmacology 25:1079–1083 · DOI
  12. Nicholson AN, Pascoe PA (1991) Monoaminergic transmission and sleep in man. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publishing, Winchester, pp 215–226
  13. Nofzinger EA, Reynolds CF III, Thas ME, Frank E, Jennings JR, Fasiczka AL, Sullivan LR, Kupfer BJ (1995) REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 152:274–276 · DOI · Paper page
  14. Oswald I, Adam K (1986) Effects of paroxetine on human sleep. Br J Clin Pharmacol 22:97–99
  15. Oswald I, Adam K, Allen S, Burack R, Spence M, Thacore V (1974) Alpha adrenergic blocker, thymoxamine, and mesoridazine both increase human REM sleep duration. Sleep Res 3:62
  16. Reynolds CF III, Kupfer DJ (1987) Sleep research in affective illness: state of the art circa 1987. Sleep 10:199–215 · DOI
  17. Rickels K, Schweizer E, Clary C, Fox I, Weise C (1994) Nefazodone and imipramine in major depression: a placebo controlled trial. Br J Psychiatry 164:802–805 · DOI
  18. Sharpley AL, Cowen PJ (1995) Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 37:85–98 · DOI
  19. Sharpley AL, Walsh AES, Cowen PJ (1992) Nefazodone — a novel antidepressant — may increase REM sleep. Biol Psychiatry 31:1070–1073 · DOI
  20. Sharpley AL, Elliott JM, Attenburrow MJ, Cowen PJ (1994) Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 33 [3/4]:467–471 · DOI
  21. Solomon RA, Sharpley AL, Cowen PJ (1989) Increased slow wave sleep with 5-HT2 receptor antagonists: detection by ambulatory EEG monitoring and automatic sleep stage analysis. J Psychopharmacol 3:125–129 · DOI
  22. Ware JC, Rose V, McBrayer R (1991) The effects of nefazodone, trazodone, buspirone and placebo on sleep and sleep related penile erections (NPT) in normal subjects. Sleep Res 20:91
  23. Yocca FD, Hyslop DK, Taylor DP (1985) Nefazodone: a potential broad spectrum antidepressant. Transact Am Soc Neurochem 16:115

Cited by

Sorted by citations

Authors
Sharpley, A. L., Williamson, D. J., Attenburrow, M. E. J., Pearson, G., Sargent, P., & Cowen, P. J.
Affiliations
University of Oxford (GB)
ORCID
Venue
Psychopharmacology
Publisher
Springer Science and Business Media LLC
Published
1996-07
Volume
126
Issue
1
Pages
50-54
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
DOI
10.1007/bf02246410
OpenAlex
W2072667078
Cited by
122
References
0
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 3
FWCI
6.31
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Medical Research Council
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
paroxetine, nefazodone, sleep architecture, REM sleep, REM latency, sleep efficiency, sleep continuity, selective serotonin reuptake inhibitors, antidepressants, polysomnography, healthy volunteers
MeSH terms
Adolescent, Adult, Analysis of Variance, Double-Blind Method, Electroencephalography, Humans, Male, Middle Aged, Piperazines, Sleep, Sleep, REM, Triazoles, Polysomnography, Selective Serotonin Reuptake Inhibitors, Paroxetine, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review